This 1996 study tested two medications—interferon-alpha and somatostatin—for treating neuroendocrine tumors (hormone-producing cancers). Interferon-alpha was found to cause fatigue and flu-like symptoms in patients, and in some cases led to low-grade chronic fatigue syndrome. When the two drugs were combined, they worked better together, improved symptoms, and were better tolerated than interferon alone.
Why It Matters
This study is relevant to ME/CFS research because it explicitly documents that interferon-alpha treatment can induce 'low-grade chronic fatigue syndrome' as a side effect in neuroendocrine tumor patients. This observation contributes to understanding how interferon-based immune interventions may trigger or exacerbate fatigue conditions, which is important for evaluating immunological hypotheses in ME/CFS and assessing safety profiles of immunomodulatory therapies.
Observed Findings
Interferon-alpha monotherapy in >350 neuroendocrine tumor patients achieved 44% biochemical response rate and 11% tumor response rate
Common side effects included flu-like symptoms and low-grade chronic fatigue syndrome
15% of patients developed autoimmune reactions
Combination IFN-alpha and octreotide in 24 carcinoid tumor patients achieved 77% biochemical response
Interferon was better tolerated when administered in combination therapy with octreotide
Inferred Conclusions
Combination IFN-alpha and octreotide improves biochemical response compared to octreotide monotherapy
Interferon-based therapy produces fatigue-related adverse effects in a subset of patients
Combination therapy may have clinical benefit through symptom improvement even without significant tumor regression
Interferon tolerability improves when used in combination rather than monotherapy
Remaining Questions
What are the mechanisms by which interferon-alpha induces chronic fatigue-like illness in treated patients?
How do the fatigue symptoms and immunological changes in interferon-treated neuroendocrine tumor patients compare to idiopathic ME/CFS?
What This Study Does Not Prove
This study does not prove that interferon-alpha causes ME/CFS in the general population or that the fatigue induced in neuroendocrine tumor patients is mechanistically identical to ME/CFS. It is observational rather than controlled, involves a specific patient population with active malignancy, and does not include formal diagnostic criteria for ME/CFS or longitudinal follow-up data on fatigue persistence.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →